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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 Item 
No Recommendation 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
 
Treatment eligibility and retention in clinical HIV care: regression-discontinuity 
evidence from South Africa 
 
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found 
 
See text of the Abstract. 
 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
 
Introduction, paragraphs 1-2 
 
Objectives 3 State specific objectives, including any prespecified hypotheses 
 
Introduction, paragraph 3 
 
Methods 
Study design 4 Present key elements of study design early in the paper 
 
Introduction, paragraph 3 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
 
Methods, paragraphs 2-3 
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
 
Methods, paragraphs 2-3 
 





Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
 




8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
 2 
more than one group 
 
Methods, paragraphs 4-8 
 
Bias 9 Describe any efforts to address potential sources of bias 
 
Methods, paragraphs 9-12 
 
Study size 10 Explain how the study size was arrived at 
 
We used all available data. Methods, paragraphs 2-3. 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why 
 
Methods, paragraphs 4-8 
 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
 
Methods, paragraphs 9-12 
 
(b) Describe any methods used to examine subgroups and interactions 
 
No subgroup analysis was conducted. 
 
(c) Explain how missing data were addressed 
 
There were no known missing data. 
 
(d) If applicable, explain how loss to follow-up was addressed 
 
Loss to follow-up was the outcome of interest. 
 
Methods, paragraphs 4-8 
 
(e) Describe any sensitivity analyses 
 
Methods, paragraph 5: Alternate definition of outcome.  
 
Methods, paragraph 10: Robustness to alternate bandwidths and using logistic 
regression instead of a linear probability model 
 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed eligible, included in the study, 
completing follow-up, and analysed 
 
Results, paragraph 1 
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(b) Give reasons for non-participation at each stage 
 
There was no non-participation as the study was an analysis of clinical records. 
 
(c) Consider use of a flow diagram 
 
We decided against a flow diagram given that participants were not recruited for the 
study – it was an analysis of existing clinical records – and the inclusion/exclusion 
criteria were very simple. 
 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
 
Results, paragraph 1 
 
(b) Indicate number of participants with missing data for each variable of interest 
 
There was no missing data. 
 
(c) Summarise follow-up time (eg, average and total amount) 
 
The analysis was not conducted using person-time. All individuals were followed for 
at least 12 months. 
 
Outcome data 15* Report numbers of outcome events or summary measures over time 
 
Results, paragraph 2 
 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and 
their precision (eg, 95% confidence interval). Make clear which confounders were 
adjusted for and why they were included 
 
Results, paragraph 2. No confounders were adjusted for as it is unnecessary in this 
quasi-experimental design (similar to an RCT). Table 1 showed that there was 
balance between exposed/unexposed in observed baseline characteristics. 
 
(b) Report category boundaries when continuous variables were categorized 
 
Methods, paragraph 5: “As secondary outcomes, we assessed the presence of a 
CD4, viral load, or ART start date within six-month intervals following a patient’s 
first CD4 count, out to two years (0-6, 6-12, 12-18, 18-24 months).” 
 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
 
All estimates were reported as absolute risk differences. 
 




Results, paragraphs 3-4 
 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
 
Discussion, paragraphs 1-6 
 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
 
Discussion, paragraphs 13-16 
 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
 
Discussion, paragraphs 17-20  
 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
 
Discussion, paragraph 14 
 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
 
See funding acknowledgments. 
 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
